Skip to Main Content

Paper Details

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Proc Natl Acad Sci U S A
314
2014
Osteosarcoma, Osteosarcoma cell lines, PI3K, RNA, TP53 gene, mTOR, mammalian target, osteosarcoma, phosphatidylinositol, phosphatidylinositol 3-kinase, primary bone tumor, rapamycin, tumor, whole-genome
Author NameAffiliation
Adam KiezunThe Broad Institute of MIT and Harvard
Eliezer M Van AllenThe Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute
Eliezer M Van AllenThe Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute
Scott L CarterThe Broad Institute of MIT and Harvard
Sylvan C BacaThe Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute
Glenn S CowleyThe Broad Institute of MIT and Harvard
Ami S BhattThe Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute
Esther RheinbayThe Broad Institute of MIT and Harvard
Chandra Sekhar PedamalluThe Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute
Chandra Sekhar PedamalluThe Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute
Elena HelmanThe Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute
Amaro Taylor-WeinerThe Broad Institute of MIT and Harvard
Aaron McKennaThe Broad Institute of MIT and Harvard
David S DeLucaThe Broad Institute of MIT and Harvard
David S DeLucaThe Broad Institute of MIT and Harvard
Michael S LawrenceThe Broad Institute of MIT and Harvard
Lauren AmbrogioThe Broad Institute of MIT and Harvard
Carrie SougnezThe Broad Institute of MIT and Harvard
Carrie SougnezThe Broad Institute of MIT and Harvard
Andrey SivachenkoThe Broad Institute of MIT and Harvard
Andrey SivachenkoThe Broad Institute of MIT and Harvard
Nikhil WagleDana-Farber Cancer Institute
Nikhil WagleDana-Farber Cancer Institute
Jaume MoraHospital Sant Joan de Deu
Jaume MoraHospital Sant Joan de Deu
Carmen de TorresHospital Sant Joan de Deu
Jorge Melendez-ZajglaNational Institute of Genomic Medicine
Charles W M Roberts
Levi A GarrawayDana-Farber Cancer Institute
Levi A GarrawayDana-Farber Cancer Institute
Stacey GabrielThe Broad Institute of MIT and Harvard
Stacey GabrielThe Broad Institute of MIT and Harvard
Eric S LanderThe Broad Institute of MIT and Harvard, Massachusetts Institute of Technology
Eric S LanderThe Broad Institute of MIT and Harvard, Massachusetts Institute of Technology
Todd R GolubThe Broad Institute of MIT and Harvard, Howard Hughes Medical Institute
Todd R GolubThe Broad Institute of MIT and Harvard, Howard Hughes Medical Institute
Stuart H OrkinHoward Hughes Medical Institute, MD 20815 gadgetz@broadinstitute.org kjaneway@partners.org.
Gad GetzThe Broad Institute of MIT and Harvard, Harvard Medical School, MA 02115 gadgetz@broadinstitute.org kjaneway@partners.org.
Gad GetzThe Broad Institute of MIT and Harvard, Harvard Medical School, MA 02115 gadgetz@broadinstitute.org kjaneway@partners.org.
Katherine A Janewaygadgetz@broadinstitute.org kjaneway@partners.org.
  • 1 - 40

Datasets